Antiplatelet Agents in Acute ST Elevation Myocardial Infarction

Kris Kumar, Harsh Golwala

Research output: Contribution to journalReview articlepeer-review

Abstract

Platelet aggregation and thrombus formation represent the basic mechanism for clinical, electrocardiographic, and biomarker changes consistent with acute coronary syndrome. Various oral and intravenous formulations of platelet function inhibitors have been developed to help decrease platelet aggregation due to acute atherosclerotic plaque rupture. In this article, we review the various mechanisms, pharmacokinetics/pharmacodynamics, and the key clinical trials related to the platelet inhibitors that form the basis for current recommendations of their use in the ST elevation myocardial infarction guidelines by the American College of Cardiology/American Heart Association.

Original languageEnglish (US)
Pages (from-to)697-708
Number of pages12
JournalAmerican Journal of Medicine
Volume135
Issue number6
DOIs
StatePublished - Jun 2022

Keywords

  • Acute coronary syndrome
  • Antiplatelet
  • STEMI

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint

Dive into the research topics of 'Antiplatelet Agents in Acute ST Elevation Myocardial Infarction'. Together they form a unique fingerprint.

Cite this